Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study

Stopped early · Not applicable

Conditions studied: Emphysema

In brief

Multicenter, randomized, assessor-blinded controlled study of safety and effectiveness of the PneumRx, Inc. RePneu Lung Volume Reduction Coil (RePneu LVRC) System

Key facts

Study ID: NCT01608490
Run by: Boston Scientific Corporation
People needed: 315
Starts: 2012-10-01
Expected to finish: 2019-07-26
Last updated by the study team: 2021-07-19

Who can join

Age: 35 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subject is greater than or equal to 35 yrs of age
CT Scan indicates bilateral emphysema, as determined by the Core Radiology Lab using the criteria presented in the "CT Scoring Plan for Core Radiology Lab"
Subject has post-bronchodilator FEV1 less than or equal to 45% predicted
Subject has Total Lung Capacity >100% predicted
Subject has residual volume (RV) greater than or equal to 175% predicted
Subject has marked dyspnea greater than or equal to 2 on mMRC scale of 0-4
Subject has stopped smoking for at least 8 weeks prior to entering the study as confirmed by a Cotinine test or other appropriate diagnostic test.
Subject has completed a pulmonary rehabilitation program within 6 mos prior to treatment and/or is regularly performing maintenance respiratory rehabilitation if initial supervised therapy occurred more than 6 mos prior to baseline testing.
Subject has received Pneumococcal and Influenza vaccinations consistent with local recommendations and/or policy.
Subject (and legal guardian, if applicable) has read, understood, and signed the Informed Consent form.

You may not qualify if…

Subject has severe homogeneous emphysema determined by Core Radiology Lab.
Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g., severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea.
Subject has a change in FEV1 of greater than 20% (or, for subjects with pre-bronchodilator FEV1 below 1L, a change of greater than 200mL) post-bronchodilator unless investigator can confirm by other means that subject does not have asthma.
Subject has DLCO of less than 20% of predicted.
Subject has severe gas exchange abnormalities, PaCO2 of greater than 55mm Hg; PaO2 of less than 45 mm Hg on room air (high altitude criterion: PaO2 of less than 30mm Hg).
Subject has a history of recurrent clinically significant respiratory infections, defined as 3 hospitalizations for respiratory infection during the year prior to enrollment.
Subject as severe pulmonary hypertension defined by right ventricular systolic pressure of greater than 50mm Hg via right heart catheterization and/or echocardiogram
Subject has an inability to walk >140m (150 yd) in 6 minutes
Subject has evidence of other severe disease (such as but not limited to lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study.
Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.
Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia.
Subject has clinically significant bronchiectasis.
Subject has giant bullae >1/3 lung volume
Subject has had previous LVR surgery, lung transplantation, lobectomy or LVR devices or other device to treat COPD in either lung.
Subject has been involved in pulmonary drug or device studies within 30 days prior to this study.
Subject is taking >20mg prednisone (or equivalent dose of a similar steroid) daily.
Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder.
Subject is on an antiplatelet agent (such as Plavix) or anticoagulant therapy (such as Heparin or Coumadin) which cannot be stopped for 7 days prior to the procedure.
Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.
Subject has a sensitivity or allergy to nitinol (nickel-titanium) or its constituent metals.
Subject has a known sensitivity to drugs required to perform bronchoscopy.
Subject has been diagnosed with alpha-1 antitrypsin deficiency (AATD).

Where it is running

University of Alabama Lung Health Center — Birmingham, Alabama, United States
Cedars Sinai Medical Center — Los Angeles, California, United States
El Camino Hospital/Palo Alto Medical Foundation — Mountain View, California, United States
National Jewish Health — Denver, Colorado, United States
Yale University School of Medicine - Yale New Haven Hospital — New Haven, Connecticut, United States
University of Florida — Gainesville, Florida, United States
Northwestern University — Chicago, Illinois, United States
University of Illinois Hospital and Health Center — Chicago, Illinois, United States
Illinois Lung and Critical Care Institute — Peoria, Illinois, United States
Pulmonary and Critical Care Associates of Baltimore — Baltimore, Maryland, United States
Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
University of Michigan Health System — Ann Arbor, Michigan, United States
Mayo Clinic — Rochester, Minnesota, United States
New York Presbyterian Columbia University Medical Center — New York, New York, United States
Duke University Medical Center — Durham, North Carolina, United States
The Cleveland Clinic — Cleveland, Ohio, United States
Temple — Philadelphia, Pennsylvania, United States
Emphysema COPD Research Center, University of Pittsburgh — Pittsburgh, Pennsylvania, United States
Medical University of South Carolina — Charleston, South Carolina, United States
Pulmonary, Critical Care & Sleep Medicine Consultants,PCCS/St. Luke's Episcopal Hospital — Houston, Texas, United States
University of Texas Health Sciences Center at San Antonio — San Antonio, Texas, United States
Franciscan Research Center — Tacoma, Washington, United States
University of Wisconsin School of Medicine & Public Health — Madison, Wisconsin, United States
Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ) — Québec, Canada
Centre Hospitalier Universitaire de Nice — Nice, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.